ReviewSkin health and disease2026
Racial and ethnic disparities in T helper 2-mediated inflammatory skin disorders.
Review in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
T helper type 2 (Th2)-mediated inflammatory skin diseases, including atopic dermatitis, discoid lupus erythematosus, systemic sclerosis, autoimmune bullous diseases and secondary lymphoedema, demonstrate significant racial and ethnic disparities in prevalence, severity and clinical outcomes. These disorders share pathogenic mechanisms involving Th2-driven immune activation, fibrosis and epidermal barrier dysfunction, leading to chronic inflammation and substantial morbidity. Black and Hispanic populations consistently experience greater disease burden, more severe clinical manifestations and reduced quality of life compared with White patients, reflecting complex interactions between biologic and socioeconomic factors. Current molecular and immunological studies suggest that ancestry-associated differences in immune polarization, cytokine signalling, autoantibody expression, fibrotic pathways and epidermal barrier biology may contribute to variation in disease phenotype and severity across Th2-mediated disorders. Black patients have demonstrated enhanced Th2 and Th22-mediated inflammation, increased IgE production, elevated interleukin (IL)-4, IL-13 and IL-22 signalling, and distinct genetic and serological profiles, including variation in filaggrin-related barrier proteins and autoantibody expression. However, mechanistic studies directly evaluating race-associated Th2 immune responses remain limited in many inflammatory skin diseases, and under-representation of diverse populations in translational research and clinical trials continues to restrict understanding of disease biology and therapeutic response. This review synthesizes the current epidemiological, molecular and immunological evidence linking race, immune dysregulation and disease heterogeneity across Th2-mediated skin disorders. Together, these findings support a growing framework in which ancestry-associated differences in immune regulation and social determinants jointly shape disparities in Th2-mediated inflammatory skin disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.